Furthermore, PDE5 inhibitors were shown to inhibit the oncogenic activity of β-catenin either by repressing its transcription or promoting its proteosomal degradation in several colon cancer cells (134–136). This evidence concerns the gene PDE5A and colonic neoplasm.